AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first ...

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...

AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...

AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active ...

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

When it comes to Parkinson's disease, we inevitably focus on "movement," such as tremors, freezing of gait, and rigidity.But ...

I am writing about the events that happened to my husband.In March 2024, my husband underwent surgery for pancreatic ...

Parkinson’s disease has long been described in terms of its most visible features: the tremor, the slowed movement, the ...

AbbVie (ABBV) gains FDA approval for Juvmo, a first-in-class Parkinson's treatment launching October 2026. Stock dips 0.29% despite breakthrough.

Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets September 23, 2026 11:00 ...

Matthew Stafford praised the toughness of Colby Parkinson and Terrance Ferguson after both played through injuries on Sunday ...

The Parkinson’s Group of the Ozarks is hosting its Pound the Pavement for Parkinson’s 5K run and one-mile walk on Oct. 3 at Rutledge Wilson Farm Park.